Biodesix

The AI engine Fit Assessment

Beta

Biodesix leverages machine learning and multi-technology approaches to enhance therapeutic options and identify biomarkers, driving personalized medicine in lung cancer diagnostics.

Blurb

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services.

HQ Location

United States

Founded

2005

Employees

201 - 500

Total funding raised

$917.77M

Last Funding Event

Post-IPO Equity, $55.00M, April 5, 2024

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Biomarker Identification

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.